10x Genomics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Serge Saxonov
- Full Time Employees
- 1,178
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6230 Stoneridge Mall Road Pleasanton CA United States of America 94588-3260
- IPO Date
- Sep 12, 2019
- CIK
- 0001770787
- Website
- 10xgenomics.com
- Similar Companies
- Business
- 10x Genomics, Inc. (NASDAQ: TXG) develops and sells instruments, consumables, and software for analyzing biological systems at the single-cell and spatial level. The company offers Chromium instruments and single cell gene expression, immune profiling, ATAC-seq, and multiome analysis kits; Visium and Xenium platforms for spatial gene expression and protein analysis; and GEM-X technology for enhanced single-cell resolution; as well as bioinformatics software including Cell Ranger, Loupe Browser, and Space Ranger. Headquartered in Pleasanton, California, and founded in 2012, 10x Genomics operates globally, serving academic institutions, biotechnology firms, pharmaceutical companies, and clinical research organizations primarily in North America, Europe, and Asia. In recent developments, the company launched GEM-X in late 2023, significantly improving single-cell capture efficiency and data quality for genomic applications; expanded its Xenium in situ platform with Xenium Prime for high-throughput spatial biology workflows; and strengthened its capabilities through strategic collaborations with leading biotech firms on multi-omics research initiatives. These advancements position 10x Genomics at the forefront of the spatial genomics and single-cell sequencing segments within the life sciences tools industry.
Company News
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
First Trust Advisors LP Invests $271,000 in 10x Genomics $TXG
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
10x Genomics Q2 Earnings Call Highlights
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics Reports Second Quarter 2026 Financial Results
10x Genomics (TXG) Upgraded to Buy: Here's Why
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
10x Genomics $TXG Shares Sold by Amova Asset Management Americas Inc.
Analyzing Mitesco (OTCMKTS:MITI) and 10x Genomics (NASDAQ:TXG)